Skip to main content

Advertisement

Log in

Management of Ibrutinib Toxicities: a Practical Guide

  • Chronic Lymphocytic Leukemias (N Jain, Section Editor)
  • Published:
Current Hematologic Malignancy Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Ibrutinib is a first-in-class, highly potent Bruton tyrosine kinase inhibitor which has become standard of care for patients with chronic lymphocytic leukaemia and other lymphoproliferative disorders. It requires indefinite administration which places emphasis on toxicity and long-term tolerance.

Recent Findings

Extensive use of ibrutinib in studies and clinical practice has better defined its full toxicity profile which has made its use more challenging than initially foreseen. In particular, dysrhythmias, bleeding, infections and constitutional symptoms have been reported and can result in dose reduction or discontinuation of ibrutinib.

Summary

Herein, we review the common as well as rare but important toxicities and discuss approach and management on a practical level. We also highlight that patients should be regularly monitored for adverse events and proactively treated to minimise side effects and avoid disruption.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as:• Of importance

  1. Cheng S, Ma J, Guo A, Lu P, Leonard JP, Coleman M, et al. BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity. Leukemia. 2014;28(3):649–57.

    Article  CAS  PubMed  Google Scholar 

  2. de Rooij MFM, Kuil A, Kater AP, Kersten MJ, Pals ST, Spaargaren M. Ibrutinib and idelalisib synergistically target BCR-controlled adhesion in MCL and CLL: a rationale for combination therapy. Blood. 2015;125(14):2306–9.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Herman SEM, Mustafa RZ, Gyamfi JA, Pittaluga S, Chang S, Chang B, et al. Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL. Blood. 2014;123(21):3286–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Ponader S, Chen SS, Buggy JJ, Balakrishnan K, Gandhi V, Wierda WG, et al. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood. 2012;119(5):1182–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373(25):2425–37.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Byrd JC, Brown JR, O’Brien S, Barrientos JC, Kay NE, Reddy NM, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371(3):213–23.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  8. Wang ML, Blum KA, Martin P, Goy A, Auer R, Kahl BS, et al. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood. 2015;126(6):739–45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369(6):507–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Treon SP, Tripsas CK, Meid K, Warren D, Varma G, Green R, et al. Ibrutinib in previously treated Waldenström’s macroglobulinemia. N Engl J Med. 2015;372(15):1430–40.

    Article  CAS  PubMed  Google Scholar 

  11. Noy A, de Vos S, Thieblemont C, Martin P, Flowers CR, Morschhauser F, et al. Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma. Blood. 2017;129(16):2224–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Burger JA, Keating MJ, Wierda WG, Hartmann E, Hoellenriegel J, Rosin NY, et al. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. Lancet Oncol. 2014;15(10):1090–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Burger JA, Sivina M, Jain N, Kim E, Kadia T, Estrov Z, et al. Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. Blood. 2019;133(10):1011–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Jaglowski SM, Jones JA, Nagar V, Flynn JM, Andritsos LA, Maddocks KJ, et al. Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study. Blood. 2015;126(7):842–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Hallek M, Kay NE, Osterborg A, Chanan-Khan AA, Mahler M, Salman M, et al. The HELIOS trial protocol: a phase III study of ibrutinib in combination with bendamustine and rituximab in relapsed/refractory chronic lymphocytic leukemia. Future Oncol. 2015;11(1):51–9.

    Article  CAS  PubMed  Google Scholar 

  16. Younes A, Sehn LH, Johnson P, Zinzani PL, Hong X, Zhu J, et al. Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-cell diffuse large B-cell lymphoma. J Clin Oncol. 2019;37(15):1285–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Dunleavy K. 472 phase I study of dose-adjusted-Teddi-R with Ibrutinib in untreated and relapsed/refractory primary CNS lymphoma. 2015.

  18. Jain P, Keating MJ, Wierda WG, Sivina M, Thompson PA, Ferrajoli A, et al. Long-term follow-up of treatment with ibrutinib and rituximab in patients with high-risk chronic lymphocytic leukemia. Clin Cancer Res. 2017;23(9):2154–8.

    Article  CAS  PubMed  Google Scholar 

  19. Maddocks KJ, Ruppert AS, Lozanski G, Heerema NA, Zhao W, Abruzzo L, et al. Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia. JAMA Oncol. 2015;1(1):80–7.

    Article  PubMed  PubMed Central  Google Scholar 

  20. O’Brien S, Furman RR, Coutre S, Flinn IW, Burger JA, Blum K, et al. Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience. Blood. 2018;131(17):1910–9.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  21. Mato AR, Nabhan C, Thompson MC, Lamanna N, Brander DM, Hill B, et al. Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis. Haematologica. 2018;103(5):874–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Psaty BM, Manolio TA, Kuller LH, Kronmal RA, Cushman M, Fried LP, et al. Incidence of and risk factors for atrial fibrillation in older adults. Circulation. 1997;96(7):2455–61.

    Article  CAS  PubMed  Google Scholar 

  23. Shanafelt TD, Parikh SA, Noseworthy PA, Goede V, Chaffee KG, Bahlo J, et al. Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL). Leuk Lymphoma. 2017;58(7):1630–9.

    Article  CAS  PubMed  Google Scholar 

  24. Dimopoulos MA, Tedeschi A, Trotman J, García-Sanz R, Macdonald D, Leblond V, et al. Phase 3 trial of ibrutinib plus rituximab in Waldenström’s macroglobulinemia. N Engl J Med. 2018;378(25):2399–410.

    Article  CAS  PubMed  Google Scholar 

  25. Fraser G, Cramer P, Demirkan F, Silva RS, Grosicki S, Pristupa A, et al. Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma. Leukemia. 2019;33(4):969–80.

    Article  CAS  PubMed  Google Scholar 

  26. Shanafelt TD, Wang XV, Kay NE, Hanson CA, O’Brien S, Barrientos J, et al. Ibrutinib–rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med. 2019;381(5):432–43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Woyach JA, Ruppert AS, Heerema NA, Zhao W, Booth AM, Ding W, et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med. 2018;379(26):2517–28.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. • O’Brien S, Hillmen P, Coutre S, Barr PM, Fraser G, Tedeschi A, et al. Safety analysis of four randomized controlled studies of ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma or mantle cell lymphoma. Clin Lymphoma Myeloma Leuk. 2018;18(10):648–57.e15. Review of safety data from four large clinical studies.

    Article  PubMed  Google Scholar 

  29. Follows GA, CLL Forum UK. Ibrutinib for relapsed/refractory CLL: an update of the UK and Ireland analysis of outcomes in 315 patients. Hematol Oncol. 2017;35(S2):238–9.

    Article  Google Scholar 

  30. Winqvist M, Andersson P-O, Asklid A, Karlsson K, Karlsson C, Lauri B, et al. Long-term real-world results of ibrutinib therapy in patients with relapsed or refractory chronic lymphocytic leukemia: 30-month follow up of the Swedish compassionate use cohort. Haematologica. 2019;104(5):e208–e10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. McMullen JR, Boey EJ, Ooi JY, Seymour JF, Keating MJ, Tam CS. Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling. Blood. 2014;124(25):3829–30.

    Article  CAS  PubMed  Google Scholar 

  32. BeiGene. Results of Phase 3 ASPEN Trial of zanubrutinib compared to ibrutinib for the treatment of patients with Waldenstrom’s Macroglobulinaemia. GLOBE NEWSWIRE. 2019.

  33. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137(2):263–72.

    Article  PubMed  Google Scholar 

  34. Jain P, Keating M, Wierda W, Estrov Z, Ferrajoli A, Jain N, et al. Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib. Blood. 2015;125(13):2062–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Thompson PA, Levy V, Tam CS, Al Nawakil C, Goudot FX, Quinquenel A, et al. Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study. Br J Haematol. 2016;175(3):462–6.

    Article  CAS  PubMed  Google Scholar 

  36. Indiana University, Department of Medicine Clinical Pharmacology. Drug Interactions.

  37. Chronic Lymphocytic Leukaemia Ibrutinib. 1858 V3. eviQ Cancer Treatments Online, Cancer Institute NSW, viewed 6th Feb 2020. 2018.

  38. Futatani T, Watanabe C, Baba Y, Tsukada S, Ochs HD. Bruton’s tyrosine kinase is present in normal platelets and its absence identifies patients with X-linked agammaglobulinaemia and carrier females. Br J Haematol. 2001;114(1):141–9.

    Article  CAS  PubMed  Google Scholar 

  39. Levade M, David E, Garcia C, Laurent PA, Cadot S, Michallet AS, et al. Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions. Blood. 2014;124(26):3991–5.

    Article  CAS  PubMed  Google Scholar 

  40. Liu J, Fitzgerald ME, Berndt MC, Jackson CW, Gartner TK. Bruton tyrosine kinase is essential for botrocetin/VWF-induced signaling and GPIb-dependent thrombus formation in vivo. Blood. 2006;108(8):2596–603.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Quek LS, Bolen J, Watson SP. A role for Bruton’s tyrosine kinase (Btk) in platelet activation by collagen. Curr Biol. 1998;8(20):1137–40.

    Article  CAS  PubMed  Google Scholar 

  42. Barr PM, Robak T, Owen C, Tedeschi A, Bairey O, Bartlett NL, et al. Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2. Haematologica. 2018;103(9):1502–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Brown JR, Hillmen P, O’Brien S, Barrientos JC, Reddy NM, Coutre SE, et al. Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL. Leukemia. 2018;32(1):83–91.

    Article  CAS  PubMed  Google Scholar 

  44. O’Brien S, Jones JA, Coutre SE, Mato AR, Hillmen P, Tam C, et al. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. Lancet Oncol. 2016;17(10):1409–18.

    Article  PubMed  CAS  Google Scholar 

  45. Brown JR, Moslehi J, Ewer MS, O’Brien SM, Ghia P, Cymbalista F, et al. Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: an integrated analysis. Br J Haematol. 2019;184(4):558–69.

    Article  CAS  PubMed  Google Scholar 

  46. Jones JA, Hillmen P, Coutre S, Tam C, Furman RR, Barr PM, et al. Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib. Br J Haematol. 2017;178(2):286–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Kunk PR, Mock J, Devitt ME, Palkimas S, Sen J, Portell CA, et al. Major bleeding with ibrutinib: more than expected. Blood. 2016;128(22):3229.

    Article  Google Scholar 

  48. Pavlik A, Barr H, Dotson E, Byrd JC, Blum KA, Awan FT, et al. Major bleeding complications among patients treated with ibrutinib and concomitant antiplatelet, anticoagulant, or Supplemental Therapy. Blood. 2016;128(22):4387.

    Article  Google Scholar 

  49. Winqvist M, Asklid A, Andersson PO, Karlsson K, Karlsson C, Lauri B, et al. Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group. Haematologica. 2016;101(12):1573–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Warfarin Antiplatelet Vascular Evaluation Trial Investigators, Anand S, Yusuf S, Xie C, Pogue J, Eikelboom J, Budaj A, et al. Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med. 2007;357(3):217–27.

  51. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345(7):494–502.

    Article  CAS  PubMed  Google Scholar 

  52. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–51.

    Article  CAS  PubMed  Google Scholar 

  53. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–92.

    Article  CAS  PubMed  Google Scholar 

  54. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–91.

    Article  CAS  PubMed  Google Scholar 

  55. Mock J, Kunk PR, Palkimas S, Sen JM, Devitt M, Horton B, et al. Risk of major bleeding with Ibrutinib. Clin Lymphoma Myeloma Leuk. 2018;18(11):755–61.

    Article  PubMed  Google Scholar 

  56. Hermosillo AJ, Spinler SA. Aspirin, clopidogrel, and warfarin: is the combination appropriate and effective or inappropriate and too dangerous? Ann Pharmacother. 2008;42(6):790–805.

    Article  CAS  PubMed  Google Scholar 

  57. Rossini R, Musumeci G, Lettieri C, Molfese M, Mihalcsik L, Mantovani P, et al. Long-term outcomes in patients undergoing coronary stenting on dual oral antiplatelet treatment requiring oral anticoagulant therapy. Am J Cardiol. 2008;102(12):1618–23.

    Article  PubMed  Google Scholar 

  58. Janssen-Cilag International. Prescribing information. 2020.

  59. Janssen Biotech I. Prescribing information. 2018.

  60. Kamel S, Horton L, Ysebaert L, Levade M, Burbury K, Tan S, et al. Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation. Leukemia. 2015;29(4):783–7.

    Article  CAS  PubMed  Google Scholar 

  61. Forum UC. Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients. Haematologica. 2016;101(12):1563–72.

    Article  CAS  Google Scholar 

  62. O’Brien SM, Furman RR, Coutre SE, Flinn IW, Burger J, Blum K, et al. Five-year experience with single-agent ibrutinib in patients with previously untreated and relapsed/refractory chronic lymphocytic leukemia/small lymphocytic leukemia. Blood. 2016;128(22):233.

    Article  Google Scholar 

  63. Brown JR. How I treat CLL patients with ibrutinib. Blood. 2018;131(4):379–86.

    Article  CAS  PubMed  Google Scholar 

  64. Gribben JG, Bosch F, Cymbalista F, Geisler CH, Ghia P, Hillmen P, et al. Optimising outcomes for patients with chronic lymphocytic leukaemia on ibrutinib therapy: European recommendations for clinical practice. Br J Haematol. 2018;180(5):666–79.

    Article  PubMed  Google Scholar 

  65. Chai KL, Rowan G, Seymour JF, Burbury K, Carney D, Tam CS. Practical recommendations for the choice of anticoagulants in the management of patients with atrial fibrillation on ibrutinib. Leuk Lymphoma. 2017;58(12):2811–4.

    Article  CAS  PubMed  Google Scholar 

  66. Services USDoHaH. Common Terminology Criteria for Adverse 830 Events (CTCAE). Version 5.0 2017 [Available from: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf. Accessed Feb 2020.

  67. Dickerson T, Wiczer T, Waller A, Philippon J, Porter K, Haddad D, et al. Hypertension and incident cardiovascular events following ibrutinib initiation. Blood. 2019;134(22):1919–28.

    Article  PubMed  PubMed Central  Google Scholar 

  68. • Barr PM, Brown JR, Hillmen P, O’Brien S, Barrientos JC, Reddy NM, et al. Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL. Blood. 2017;129(19):2612–5. Describes prevalence of PJP in patients treated with ibrutinib and helped guide our PJP prophylaxis recommendations.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Coutre SE, Byrd JC, Hillmen P, Barrientos JC, Barr PM, Devereux S, et al. Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. Blood Adv. 2019;3(12):1799–807.

    Article  PubMed  PubMed Central  Google Scholar 

  70. Morrison VA. Infectious complications in patients with chronic lymphocytic leukemia: pathogenesis, spectrum of infection, and approaches to prophylaxis. Clin Lymphoma Myeloma. 2009;9(5):365–70.

    Article  CAS  PubMed  Google Scholar 

  71. Badoux XC, Keating MJ, O’Brien S, Wierda WG, Faderl S, Estrov Z, et al. Final analysis of a phase 2 study of lenalidomide and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). Blood. 2011;118(21):980.

    Article  Google Scholar 

  72. Sun C, Tian X, Lee YS, Gunti S, Lipsky A, Herman SEM, et al. Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib. Blood. 2015;126(19):2213–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Cheng MP, Kusztos AE, Gustine JN, Dryden-Peterson SL, Dubeau TE, Woolley AE, et al. Low risk of Pneumocystis jirovecii pneumonia and invasive aspergillosis in patients with Waldenström macroglobulinaemia on ibrutinib. Br J Haematol. 2019;185(4):788–90.

    Article  PubMed  Google Scholar 

  74. Ryan CE CM, Issa NC, Brown JR, Davids MS. Pneumocystis jirovecii pneumonia and invasive fungal prophylaxis practices in CLL patients treated with BTK inhibitors. Abstract.

  75. Ahn IE, Jerussi T, Farooqui M, Tian X, Wiestner A, Gea-Banacloche J. Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib. Blood. 2016;128(15):1940–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  76. Byrd JC, Furman RR, Coutre SE, Burger JA, Blum KA, Coleman M, et al. Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood. 2015;125(16):2497–506.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Giridhar KV, Shanafelt T, Tosh PK, Parikh SA, Call TG. Disseminated herpes zoster in chronic lymphocytic leukemia (CLL) patients treated with B-cell receptor pathway inhibitors. Leuk Lymphoma. 2017;58(8):1973–6.

    Article  PubMed  Google Scholar 

  78. Hammond SP, Chen K, Pandit A, Davids MS, Issa NC, Marty FM. Risk of hepatitis B virus reactivation in patients treated with ibrutinib. Blood. 2018;131(17):1987–9.

    Article  CAS  PubMed  Google Scholar 

  79. Byrd JC, Hillmen P, O’Brien SM, Barrientos JC, Reddy NM, Coutre S, et al. Long-term efficacy and safety with ibrutinib (ibr) in previously treated chronic lymphocytic leukemia (CLL): up to four years follow-up of the RESONATE study. J Clin Oncol. 2017;35(15_suppl):7510.

    Article  Google Scholar 

  80. Douglas AP, Trubiano JA, Barr I, Leung V, Slavin MA, Tam CS. Ibrutinib may impair serological responses to influenza vaccination. Haematologica. 2017;102(10):e397–e9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Andrick B, Alwhaibi A, DeRemer D, Quershi S, Khan R, Shenoy S, et al. Antibody response to pneumococcal conjugate vaccine (PCV13) in chronic lymphocytic leukemia patients receiving ibrutinib. Blood. 2016;128(22):5597.

    Article  Google Scholar 

  82. Sun C, Gao J, Couzens L, Tian X, Farooqui MZ, Eichelberger MC, et al. Seasonal influenza vaccination in patients with chronic lymphocytic leukemia treated with Ibrutinib. JAMA Oncol. 2016;2(12):1656–7.

    Article  PubMed  PubMed Central  Google Scholar 

  83. Wang B, Mufti G, Agarwal K. Reactivation of hepatitis B virus infection in patients with hematologic disorders. Haematologica. 2019;104(3):435–43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. Barrientos JC, O’Brien S, Brown JR, Kay NE, Reddy NM, Coutre S, et al. Improvement in parameters of hematologic and immunologic function and patient well-being in the phase III RESONATE study of ibrutinib versus ofatumumab in patients with previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma. Clin Lymphoma Myeloma Leuk. 2018;18(12):803–13.e7.

    Article  PubMed  PubMed Central  Google Scholar 

  85. Iberri DJ, Kwong BY, Stevens LA, Coutre SE, Kim J, Sabile JM, et al. Ibrutinib-associated rash: a single-centre experience of clinicopathological features and management. Br J Haematol. 2018;180(1):164–6.

    Article  PubMed  Google Scholar 

  86. Bitar C, Farooqui MZH, Valdez J, Saba NS, Soto S, Bray A, et al. Hair and nail changes during long-term therapy with ibrutinib for chronic lymphocytic leukemia. JAMA Dermatol. 2016;152(6):698–701.

    Article  PubMed  PubMed Central  Google Scholar 

  87. Woyach JA, Smucker K, Smith LL, Lozanski A, Zhong Y, Ruppert AS, et al. Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. Blood. 2014;123(12):1810–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  88. • Guha A, Derbala MH, Zhao Q, Wiczer TE, Woyach JA, Byrd JC, et al. Ventricular arrhythmias following ibrutinib initiation for lymphoid malignancies. J Am Coll Cardiol. 2018;72(6):697–8. Highlights increased risk of ventricular arrhythmias in patients on ibrutinib.

    Article  PubMed  PubMed Central  Google Scholar 

  89. • Lampson BL, Yu L, Glynn RJ, Barrientos JC, Jacobsen ED, Banerji V, et al. Ventricular arrhythmias and sudden death in patients taking ibrutinib. Blood. 2017;129(18):2581–4. Highlights increased risk of ventricular arrhythmias in patients on ibrutinib.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  90. Chanan-Khan A, Cramer P, Demirkan F, Fraser G, Silva RS, Grosicki S, et al. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Lancet Oncol. 2016;17(2):200–11.

    Article  CAS  PubMed  Google Scholar 

  91. Becker LB, Han BH, Meyer PM, Wright FA, Rhodes KV, Smith DW, et al. Racial differences in the incidence of cardiac arrest and subsequent survival. N Engl J Med. 1993;329(9):600–6.

    Article  CAS  PubMed  Google Scholar 

  92. Chugh SS, Jui J, Gunson K, Stecker EC, John BT, Thompson B, et al. Current burden of sudden cardiac death: multiple source surveillance versus retrospective death certificate-based review in a large U.S. community. J Am Coll Cardiol. 2004;44(6):1268–75.

    Article  PubMed  Google Scholar 

  93. Rothwell PM, Coull AJ, Silver LE, Fairhead JF, Giles MF, Lovelock CE, et al. Population-based study of event-rate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study). Lancet. 2005;366(9499):1773–83.

    Article  CAS  PubMed  Google Scholar 

  94. Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, et al. Ibrutinib and venetoclax for first-line treatment of CLL. N Engl J Med. 2019;380(22):2095–103.

    Article  CAS  PubMed  Google Scholar 

  95. • Mato AR, Islam P, Daniel C, Strelec L, Kaye AH, Brooks S, et al. Ibrutinib-induced pneumonitis in patients with chronic lymphocytic leukemia. Blood. 2018;127(8):1064–7. Describes ibrutinib-induced pneumonitis which is a rare but potentially life-threatening toxicity.

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Constantine S. Tam.

Ethics declarations

Conflict of Interest

CT reports honoraria and research funding from AbbVie, Janssen and Beigene, outside of the submitted work. ML declares no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Chronic Lymphocytic Leukemias

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lasica, M., Tam, C.S. Management of Ibrutinib Toxicities: a Practical Guide. Curr Hematol Malig Rep 15, 177–186 (2020). https://doi.org/10.1007/s11899-020-00576-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11899-020-00576-3

Keywords

Navigation